Eight patent-sensitive molecules were admitted to China’s price-cutting round on one condition: the bidder signs an intellectual property undertaking and carries the risk.
A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.
Scilex Holding Company has announced an exclusive global license from Datavault AI to tokenize and monetize genomic, diagnostic, and therapeutic data ushering in a new digital framework for valuing real-world biotech assets. The agreement allows Scilex to use Datavault’s proprietary AI-driven platform to create a Biotech Exchange, a marketplace designed to securely trade and fund … Read more